Analyst Price Targets — IFRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 3, 2025 11:10 am | — | Leerink Partners | $2.00 | $0.99 | TheFly | InflaRx downgraded to Market Perform from Outperform at Leerink |
| May 29, 2025 8:50 am | — | Raymond James | $2.00 | $0.85 | TheFly | InflaRx downgraded to Outperform from Strong Buy at Raymond James |
| January 6, 2023 4:32 am | — | H.C. Wainwright | $6.00 | $2.92 | Benzinga | HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $6 |
Latest News for IFRX
JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity. These results further…
JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Raymond James 2026 Biotech Innovation Symposium. Details are as follows:
Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab in pyoderma gangrenosum (PG) were featured in an oral presentation during the Late-Breaking Research abstract session at the 2026 American Academy of Dermatology (AAD)…
InflaRx N.V. (NASDAQ: IFRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy recommendation to
InflaRx (NASDAQ: IFRX - Get Free Report) and Athira Pharma (NASDAQ: ATHA - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends. Risk and Volatility InflaRx has a beta of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IFRX.
U.S. House Trading
No House trades found for IFRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.